Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ: GH )

31.67 +0.54 (+1.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022
Upgrades 
Via Benzinga
Stephens Starts Coverage On This Precision Oncology Company With 66% Upside
Via Benzinga
Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022
From Guardant Health, Inc.
Via Business Wire
Why Guardant Health Topped the Market on Thursday
Add another name to the list of the cancer-diagnostic company's bulls. 
Via The Motley Fool
Analyst Ratings for Guardant Health
Analysts have provided the following ratings for Guardant Health (NASDAQ:GH) within the last quarter: 
Via Benzinga
Netflix, Biogen And Other Big Gainers From Wednesday
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Via Benzinga
Analyst Ratings for Guardant Health
Within the last quarter, Guardant Health (NASDAQ:GH) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
Upgrades 
Via Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
Via Benzinga
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."  The... 
Via Benzinga
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
From Guardant Health, Inc.
Via Business Wire
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
From Guardant Health, Inc.
Via Business Wire
Lululemon, Smartsheet, Okta, And Other Big Gainers From Friday
U.S. stocks closed lower with the Dow Jones dropping more than 300 points on Friday. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
No More Free COVID-19 At-Home Tests, Federal Government Says
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au 
Via Benzinga
Why Micro Focus International Is Trading Higher By Around 94%; Here Are 28 Stocks Moving Premarket
Gainers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Guardant Health's Return On Capital Employed Insights
Benzinga Pro data, Guardant Health (NASDAQ:GH) reported Q2 sales of $109.14 million. Earnings fell to a loss of $229.43 million, resulting in a 86.18% decrease from last quarter. 
Via Benzinga
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
From Guardant Health, Inc.
Via Business Wire
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
Via Benzinga
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
From Guardant Health, Inc.
Via Business Wire
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. 
Via Benzinga
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference
From Guardant Health, Inc.
Via Business Wire
Uber Dumped By Large Shareholder As Billionaire's 'Vision' Suffers Investment Struggles
After reporting one of its largest losses ever, SoftBank Group Corp (OTC: SFTBY) has turned to alternative methods to regain lost capital. 
Via Benzinga
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.